Molecular testing to help diagnose COVID-19 (test code 39448)
As of January 5, 2020, we have reported results of approximately 28.9 million COVID-19 molecular diagnostic tests for patients and providers in the United States. We will continue to prioritize and expedite testing for priority patients (i.e., hospitalized patients, individuals in long-term care such as nursing homes, and presurgical patients) as we have done since the beginning of the pandemic. For the general population, please limit COVID-19 molecular testing to symptomatic and recently exposed patients per the current CDC guidelines.
This website is kept up to date and represents current average turnaround times nationally.
At Quest, we continue to prioritize molecular testing and TAT for Priority patients. Priority testing parameters are defined as hospitalized, long-term care (LTC), and presurgical patients.
less than 2 days
COVID-19 is unpredictable, and we will continue to monitor the situation closely should changing dynamics affecting demand, supplies, and other factors cause our expectations for turnaround time to slip.
less than 2 days
Due to growing testing volumes, results may take longer to receive. Please contact your Quest representative to obtain the turnaround time at your specific laboratory location or for more information around COVID-19 testing.
COVID-19 testing statements
- The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
- All tests have been authorized by FDA under EUAs for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses, pathogens; and,
- All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.